Form 4: Rhythm Pharma CTO Shulman Reports RSU Vesting, Stock Acquisition

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, reported the vesting of restricted stock units and the acquisition of common stock, with shares withheld for tax obligations.

Summary

• Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, Inc. (RYTM), reported transactions related to his beneficial ownership.
• On February 1, 2026, Shulman acquired 16,968 shares of common stock through the vesting of restricted stock units (RSUs).
• Concurrently, 6,507 shares of common stock were disposed of at a price of $108.99 per share to cover withholding taxes associated with the RSU vesting.
• Following these transactions, Shulman beneficially owns 18,970 shares of common stock directly.
• Several tranches of restricted stock units vested, totaling 16,968 units, which converted into common stock.
• Remaining unvested restricted stock units are reported as 3,937, 8,250, and 18,750 for different grants, with future vesting dates extending to February 1, 2029.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. It reflects routine executive compensation activity, indicating continued executive alignment with company performance through equity holdings, despite a portion being sold for taxes.

Positives

• The vesting of restricted stock units and subsequent acquisition of common stock indicates the executive's continued equity participation in the company.
• The executive continues to hold a significant number of shares (18,970 common stock and 30,937 unvested RSUs), aligning his interests with shareholders.

Negatives

• A portion of the vested shares (6,507 shares) was sold to cover tax obligations, which is a common practice but reduces the executive's direct shareholding from the gross vested amount.

Future Outlook

No specific forward-looking statements or guidance are provided beyond the future vesting schedules of the RSUs.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executive compensation and insider transactions. The vesting of restricted stock units is a common component of executive compensation packages in the biotechnology and pharmaceutical industry, designed to align executive incentives with long-term shareholder value. This filing does not provide specific insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• This transaction is a routine vesting and tax withholding event, common across publicly traded companies, particularly in high-growth sectors like biotechnology.
• For example, executives at companies like Vertex Pharmaceuticals or Regeneron Pharmaceuticals frequently report similar RSU vesting and tax-related dispositions as part of their compensation structures.
• The specific share price of $108.99 for tax withholding reflects the market value at the time of the transaction, which would be compared to peer company stock performance on that date.

Related Party Transactions

• The reported transactions are insider dealings related to executive compensation, specifically the vesting of restricted stock units and the subsequent acquisition and tax-related disposition of common stock by the Chief Technical Officer.

Stakeholder Impact

• Shareholders: The filing indicates continued equity ownership by a key executive, which generally aligns management's interests with shareholder value. The sale of shares for tax purposes is a standard practice and not indicative of a lack of confidence.

Next Steps

• Future vesting of remaining restricted stock units on various dates up to February 1, 2029.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (RSU vesting and tax-related share disposition). It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The executive's continued equity holdings are a neutral to slightly positive signal, but insufficient to alter a broader investment thesis.

Keywords

Rhythm Pharmaceuticals, RYTM, Joseph Shulman, Chief Technical Officer, Form 4, SEC filing, insider transaction, restricted stock units, RSU vesting, common stock, equity compensation, beneficial ownership, stock acquisition, tax withholding